Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Holman

Showing results (101-110 of 833) with videos related to

Pageof 84
Sort By:
Lancet (London, England)|September 23, 2014
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' replyRury R Holman, Harald Sourij, Robert M Califf
Developments in Biological Standardization|January 1, 1978
Clinical experience with Wyeth Laboratories HDCS rabies vaccine at the Center for Disease ControlW G Winkler, L J Anderson, R Holman
Diabetes Research and Clinical Practice|March 28, 2025
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysisErnesto Maddaloni, Ruth L Coleman, Rury R Holman
Diabetes Care|July 30, 2002
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61Stephen Colagiuri, Carole A Cull, Rury R Holman, et al.
Diabetologia|July 1, 1997
Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes StudyR C Turner, H Millns, R R Holman
Diabetic Medicine : a Journal of the British Diabetic Association|September 1, 1987
Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplementR R Holman, J Steemson, R C Turner
Lancet (London, England)|June 10, 2014
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesRury R Holman, Harald Sourij, Robert M Califf
Diabetologia|March 27, 2015
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]Jonathan C Levy, Axel Riefflin, Rury R Holman
Diabetes Care|May 22, 2019
Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163Eberhard Standl, Jennifer B Green, Rury R Holman, et al.
The Journal of the American Board of Family Practice|September 10, 2004
Continuity of care and patient satisfaction in a family practice clinicEric D Morgan, Michael Pasquarella, John R Holman
Pageof 84

Showing results (101-110 of 833) with videos related to

Sort By:
Pageof 84
Lancet (London, England)|September 23, 2014
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' replyRury R Holman, Harald Sourij, Robert M Califf
Developments in Biological Standardization|January 1, 1978
Clinical experience with Wyeth Laboratories HDCS rabies vaccine at the Center for Disease ControlW G Winkler, L J Anderson, R Holman
Diabetes Research and Clinical Practice|March 28, 2025
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysisErnesto Maddaloni, Ruth L Coleman, Rury R Holman
Diabetes Care|July 30, 2002
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61Stephen Colagiuri, Carole A Cull, Rury R Holman, et al.
Diabetologia|July 1, 1997
Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes StudyR C Turner, H Millns, R R Holman
Diabetic Medicine : a Journal of the British Diabetic Association|September 1, 1987
Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplementR R Holman, J Steemson, R C Turner
Lancet (London, England)|June 10, 2014
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesRury R Holman, Harald Sourij, Robert M Califf
Diabetologia|March 27, 2015
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]Jonathan C Levy, Axel Riefflin, Rury R Holman
Diabetes Care|May 22, 2019
Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163Eberhard Standl, Jennifer B Green, Rury R Holman, et al.
The Journal of the American Board of Family Practice|September 10, 2004
Continuity of care and patient satisfaction in a family practice clinicEric D Morgan, Michael Pasquarella, John R Holman
Pageof 84